Semaglutide
GLP-1 · s.c. / oral · Novo Nordisk
Summary
- Also known as
- Wegovy / Ozempic / Rybelsus
- Mechanism
- GLP-1
- Route
- s.c. / oral
- Company
- Novo Nordisk
- Highest development stage
- approved
- Status (as of data cut)
- Approved: obesity, T2D, MACE reduction, CKD in T2D (Ozempic), MASH (Wegovy US 2025; Kayshild EU 2026); oral Wegovy tablets verify
- Next milestone
- 7.2 mg (STEP UP)
Sources for the status
Indications: regulatory and evidence status
| Indication | Code | Status | Evidence |
|---|---|---|---|
| Obesity | 4 approved / in label | FDA: Wegovy (injection and tablets); EMA: Wegovy | Wegovy US label (2026); Wegovy EPAR |
| T2D | 4 approved / in label | FDA: Ozempic, Rybelsus; EMA: Ozempic, Rybelsus | Ozempic EPAR |
| CV outcomes | 4 approved / in label | FDA label: MACE reduction in T2D with CVD (Ozempic, SUSTAIN-6/SOUL) and in obesity with CVD (Wegovy, SELECT) | SELECT; SOUL; SUSTAIN-6 |
| CKD | 4 approved / in label | FDA label (Ozempic): reduce risk of kidney failure, eGFR decline and CV death in T2D with CKD | FLOW |
| HFpEF | 3 positive phase 3 | Positive phase 3 on symptoms and function; not a labelled indication | STEP-HFpEF; STEP-HFpEF DM |
| MASH | 4 approved / in label | FDA: Wegovy, accelerated approval (MASH F2–F3, 2025); EMA: Kayshild (2026); NMPA (China): Wegovy, September 2026 | Wegovy US label; Kayshild EPAR; ESSENCE; NMPA approval in China (Yicai, 10 Sep 2026) |
| Sleep apnoea | 0 no data | No phase 3 in sleep apnoea registered | |
| Knee OA | 3 positive phase 3 | Positive phase 3 (pain and weight); not a labelled indication | STEP 9 |
| Alzheimer's | -1 negative phase 3/4 | evoke and evoke+ did not meet the primary endpoint | evoke; evoke+ |
4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.
US prescribing information: indications
Verbatim section 1 of the current FDA label (DailyMed), as checked by the atlas.
OZEMPIC US label 30.01.2026
1 INDICATIONS AND USAGE RYBELSUS and OZEMPIC tablets are indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. • to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events. RYBELSUS and OZEMPIC tablets are glucagon-like peptide-1 (GLP-1) receptor agonists indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events. ( 1 )
Ozempic US label 30.07.2026
1 INDICATIONS AND USAGE OZEMPIC is indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease. • to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease. OZEMPIC is a glucagon-like peptide 1 (GLP-1) receptor agonist indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) • to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease. ( 1 ) • to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease. ( 1 )
WEGOVY US label 23.04.2024
1 INDICATIONS AND USAGE WEGOVY is indicated in combination with a reduced calorie diet and increased physical activity: • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight. • to reduce excess body weight and maintain weight reduction long term in: o Adults and pediatric patients aged 12 years and older with obesity o Adults with overweight in the presence of at least one weight-related comorbid condition. Limitations of Use • WEGOVY contains semaglutide. Coadministration with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended. WEGOVY is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated in combination with a reduced calorie diet and increased physical activity: • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight (1) . • to reduce excess body weight and maintain weight reduction long term in: o Adults and pediatric patients aged 12 years and older with obesity o Adults with overweight in the presence of at least one weight-related comorbid condition (1) . Limitations of Use: • Coadministration with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommen
Trial arms: weight, HbA1c and tolerability
| Trial | Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OASIS 4 | oral semaglutide 25 mg | obesity | 64 | 307 | −16.6 % vs −2.7 % Δ −13.9 pp | −13.6 % vs −2.2 % Δ −11.4 pp | −0.3 vs −0.1 | 6.9 vs 5.9 | 18.5 vs 25.5 | 46.6 vs 18.6 | 30.9 vs 5.9 | 3.9 vs 8.8 | −6.8 vs −5.4 | verified |
| STEP 1 | semaglutide 2.4 mg | obesity | 68 | 1961 | −16.9 % vs −2.4 % Δ −14.5 pp | −14.9 % vs −2.4 % Δ −12.5 pp | −0.5 vs −0.1 | 7.0 vs 3.1 | — | 44.2 vs 17.4 | 24.8 vs 6.6 | 9.8 vs 6.4 | −6.2 vs −1.1 | verified |
| STEP 2 | semaglutide 2.4 mg | t2d | 68 | 1210 | −10.6 % vs −3.1 % Δ −7.5 pp | −9.6 % vs −3.4 % Δ −6.2 pp | −1.6 vs −0.4 | 6.2 vs 3.5 | 11.6 vs 13.9 | 33.7 vs 9.2 | 21.8 vs 2.7 | 9.9 vs 9.2 | −3.9 vs −0.5 | verified |
| STEP UP | semaglutide 7.2 mg | obesity | 72 | 1407 | −20.7 % vs −2.4 % Δ −18.3 pp | −18.7 % vs −3.9 % Δ −14.8 pp | −0.3 vs −0.0 | 5.4 vs 1.0 | 11.6 vs 29.4 | — | — | 6.8 vs 5.5 | −9.9 vs −4.4 | verified |
| STEP UP | semaglutide 2.4 mg | obesity | 72 | 1407 | −17.5 % vs −2.4 % Δ −15.1 pp | −15.6 % vs −3.9 % Δ −11.7 pp | −0.3 vs −0.0 | 4.0 vs 1.0 | 11.9 vs 29.4 | — | — | 10.9 vs 5.5 | −8.7 vs −4.4 | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- semaglutide 2.4 mg: Per-arm discontinuation is in the supplementary figure only.
Verbatim quotes from the source (33)
- semaglutide 2.4 mg · ae_dc · Table 3
| Adverse events leading to discontinuation of drug or placebo | 92 (7.0) | 123 | 7.2 | 20 (3.1) | 23 | 2.8 |
- semaglutide 2.4 mg · nausea · Table 3
| Nausea | 577 (44.2) | 1068 | 62.6 | 114 (17.4) | 146 | 17.6 |
- semaglutide 2.4 mg · vomiting · Table 3
| Vomiting | 324 (24.8) | 636 | 37.3 | 43 (6.6) | 52 | 6.3 |
- semaglutide 2.4 mg · sae · Table 3
| Serious adverse events | 128 (9.8) | 164 | 9.6 | 42 (6.4) | 53 | 6.4 |
- semaglutide 2.4 mg · hba1c · Table 2 (supportive secondary)
| Glycated hemoglobin — percentage points | -0.45 | -0.15 | -0.29 (-0.32 to -0.26) | | |
- semaglutide 7.2 mg · weight_eff · Results, paragraph 3; Figure 2B
Using the trial product estimand, the mean change in bodyweight was –20·7% (SE 0·3) with semaglutide 7·2 mg
- semaglutide 7.2 mg · weight_tp · Table 2
–18·7% (0·4); n=950
- semaglutide 7.2 mg · ae_dc · Results, safety paragraphs; Table 3
Permanent discontinuation of the trial product occurred in 54 (5·4%) of 1004 participants receiving semaglutide 7·2 mg
- semaglutide 7.2 mg · disc_any · Figure 1
117 discontinued treatment
- semaglutide 7.2 mg · sae · Results; Table 3
Serious adverse events were reported by 68 (6·8%) of 1004 participants receiving semaglutide 7·2 mg
- semaglutide 7.2 mg · hba1c · Table 2
–0·32 (0·01); n=938
- semaglutide 7.2 mg · sbp · Table 2
–9·9 (0·4); n=949
- semaglutide 2.4 mg · ae_dc · Results, Safety (text) + Table 3; safety set N=1004/201/201
Permanent discontinuation of the trial product occurred in 54 (5·4%) of 1004 participants receiving semaglutide 7·2 mg, eight (4·0%) of 201 receiving semaglutide 2·4 mg, and two (1·0%) of 201 receiving placebo
- semaglutide 2.4 mg · disc_any · Figure 1 trial profile
24 discontinued treatment 8 adverse events
- semaglutide 2.4 mg · sae · Results, Safety (text) + Table 3; safety set N=1004/201/201
Serious adverse events were reported by 68 (6·8%) of 1004 participants receiving semaglutide 7·2 mg, 22 (10·9%) of 201 receiving semaglutide 2·4 mg, and 11 (5·5%) of 201 receiving placebo
- semaglutide 2.4 mg · hba1c · Table 2 (supportive secondary)
HbA1c, percentage points –0·32 (0·01); n=938 –0·30 (0·02); n=186 –0·02 (0·03); n=167
- semaglutide 2.4 mg · sbp · Table 2 (supportive secondary, Blood pressure)
Systolic –9·9 (0·4); n=949 –8·7 (1·0); n=188 –4·4 (0·8); n=171
- semaglutide 2.4 mg · weight_eff · Results, paragraph 2 (Figure 2B)
The change for the trial product estimand was −10·6% (SE 0·4) for semaglutide 2·4 mg versus −3·1% (SE 0·4) for placebo
- semaglutide 2.4 mg · weight_tp · Table 2
Bodyweight change from baseline to week 68 (SE), % −9·64% (0·4) −6·99% (0·4) −3·42% (0·4)
- semaglutide 2.4 mg · ae_dc · Table 3
Adverse events leading to trial product discontinuation 25 (6·2%) 34 6·4
- semaglutide 2.4 mg · disc_any · Figure 1 (trial profile)
47 discontinued treatment prematurely*
- semaglutide 2.4 mg · nausea · Table 3
Nausea 136 (33·7%) 249 46·7
- semaglutide 2.4 mg · vomiting · Table 3
Vomiting 88 (21·8%) 188 35·3
- semaglutide 2.4 mg · sae · Table 3
Serious adverse events 40 (9·9%) 71 13·3
- semaglutide 2.4 mg · hba1c · Table 2
Change from baseline to week 68 (SE) −1·6% (0·1) −1·5% (0·1) −0·4% (0·1)
- semaglutide 2.4 mg · sbp · Table 2
Change from baseline to week 68 (SE) −3·9 (0·7) −2·9 (0·9) –0·5 (0·8)
- oral semaglutide 25 mg · ae_dc · Table 3
Adverse events leading to discontinuation of semaglutide or placebo 14 (6.9) 14 5.6 6 (5.9)
- oral semaglutide 25 mg · disc_any · Results, Participants
243 participants (79.2%) were receiving sema- glutide or placebo at the end of the 64-week trial period — 167 (81.5%) in the oral semaglutide group and 76 (74.5%) in the placebo group; 290
- oral semaglutide 25 mg · nausea · Table 3
Nausea 95 (46.6) 157 62.5 19 (18.6) 27 22.2
- oral semaglutide 25 mg · vomiting · Table 3
Vomiting 63 (30.9) 105 41.8 6 (5.9) 6 4.9
- oral semaglutide 25 mg · sae · Table 3
Serious adverse events 8 (3.9) 17 6.8 9 (8.8) 13 10.7
- oral semaglutide 25 mg · hba1c · Table 2
Glycated hemoglobin — percentage points –0.3 –0.1 –0.2 (–0.3 to –0.2)
- oral semaglutide 25 mg · sbp · Table 2
Systolic blood pressure — mm Hg –6.8 –5.4 –1.4 (–4.6 to 1.8)
Outcome trials
Cardiovascular and kidney outcome trials
SELECT semaglutide 2.4 mg vs placebo · Obesity + established CVD, no diabetes · n = 17604 · 2023 verified
| Endpoint | HR | 95 % CI | Events, drug vs control | Status |
|---|---|---|---|---|
| 3-point MACE primary Primary composite: CV death, nonfatal MI, or nonfatal stroke (time to first event) | 0.80 | 0.72–0.90 | 569 vs 701 | verified |
| Cardiovascular death Death from cardiovascular causes (first confirmatory secondary endpoint) | 0.85 | 0.71–1.01 | 223 vs 262 | verified |
| All-cause death Death from any cause (third confirmatory secondary endpoint) | 0.81 | 0.71–0.93 | 375 vs 458 | verified |
| Myocardial infarction Nonfatal myocardial infarction only (supportive secondary endpoint); fatal MI not reported separately | 0.72 | 0.61–0.85 | 234 vs 322 | verified |
| Stroke Nonfatal stroke only (supportive secondary endpoint); fatal stroke not reported separately | 0.93 | 0.74–1.15 | 154 vs 165 | verified |
| Hospitalisation for heart failure Hospitalization or urgent medical visit for heart failure (supportive secondary endpoint) | 0.79 | 0.60–1.03 | 97 vs 122 | verified |
| CV death or worsening HF Heart failure composite: CV death or hospitalization or urgent medical visit for heart failure (second confirmatory secondary endpoint) | 0.82 | 0.71–0.96 | 300 vs 361 | verified |
| Kidney composite Nephropathy composite (supportive secondary): renal death, long-term renal replacement therapy, persistent eGFR <15, persistent 50% eGFR reduction, or persisten | 0.78 | 0.63–0.96 | 155 vs 198 | verified |
| Expanded MACE (MACE + revasc. + UA) Cardiovascular expanded composite: death from CV causes, nonfatal MI, nonfatal stroke, coronary revascularization, or unstable angina leading to hospitalization | 0.80 | 0.73–0.87 | 873 vs 1074 | verified |
| New-onset diabetes Glycated hemoglobin level >=6.5% (glycemic threshold for diabetes) in a population without diabetes at baseline; patients randomized in error with baseline HbA1c >6.5% excluded (8800 vs 8797 analysed) | 0.27 | 0.24–0.31 | 306 vs 1059 | verified |
| Coronary revascularisation Coronary revascularization | 0.77 | 0.68–0.87 | 473 vs 608 | verified |
| Hospitalisation for unstable angina Unstable angina leading to hospitalization | 0.87 | 0.67–1.13 | 109 vs 124 | verified |
Verbatim quotes (12)
- 3-point MACE · Results, Efficacy End Points; Table 2
occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval [CI], 0.72 to 0.90
- Cardiovascular death · Results, Efficacy End Points; Table 2
occurred in 223 patients (2.5%) in the semaglutide group and in 262 patients (3.0%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.71 to 1.01; P=0.07
- All-cause death · Table 2
Death from any cause | 375 (4.3) | 458 (5.2) | 0.81 (0.71 to 0.93)
- Myocardial infarction · Table 2
Nonfatal myocardial infarction | 234 (2.7) | 322 (3.7) | 0.72 (0.61 to 0.85)
- Stroke · Table 2
Nonfatal stroke | 154 (1.7) | 165 (1.9) | 0.93 (0.74 to 1.15)
- Hospitalisation for heart failure · Table 2
Hospitalization or urgent medical visit for heart failure | 97 (1.1) | 122 (1.4) | 0.79 (0.60 to 1.03)
- CV death or worsening HF · Table 2
Heart failure composite end point§ | 300 (3.4) | 361 (4.1) | 0.82 (0.71 to 0.96)
- Kidney composite · Table 2
Nephropathy composite end point‖‖ | 155 (1.8) | 198 (2.2) | 0.78 (0.63 to 0.96)
- Expanded MACE (MACE + revasc. + UA) · Table 2, supportive secondary end points
| Cardiovascular expanded composite end point∥ | 873 (9.9) | 1074 (12.2) | 0.80 (0.73 to 0.87) | NA |
- New-onset diabetes · Table 2, supportive secondary end points
| Glycated hemoglobin level ≥6.5%†† | 306 (3.5) | 1059 (12.0) | 0.27 (0.24 to 0.31) | NA |
- Coronary revascularisation · Table 2, supportive secondary end points
| Coronary revascularization | 473 (5.4) | 608 (6.9) | 0.77 (0.68 to 0.87) | NA |
- Hospitalisation for unstable angina · Table 2, supportive secondary end points
| Unstable angina leading to hospitalization | 109 (1.2) | 124 (1.4) | 0.87 (0.67 to 1.13) | NA |
FLOW semaglutide 1.0 mg vs placebo · T2D + CKD · n = 3533 · 2024 verified
| Endpoint | HR | 95 % CI | Events, drug vs control | Status |
|---|---|---|---|---|
| 3-point MACE Major cardiovascular events: nonfatal MI, nonfatal stroke, or CV death (confirmatory secondary outcome, time to first event) | 0.82 | 0.68–0.98 | 212 vs 254 | verified |
| Cardiovascular death Death from cardiovascular causes (includes undetermined causes adjudicated by the committee) | 0.71 | 0.56–0.89 | 123 vs 169 | verified |
| All-cause death Death from any cause (confirmatory secondary outcome) | 0.80 | 0.67–0.95 | 227 vs 279 | verified |
| Myocardial infarction Nonfatal myocardial infarction only (fatal MI not separately reported) | 0.80 | 0.55–1.15 | 52 vs 64 | verified |
| Stroke Nonfatal stroke only (fatal stroke not separately reported) | 1.22 | 0.84–1.77 | 63 vs 51 | verified |
| Major kidney disease events primary Major kidney disease events: kidney failure (long-term dialysis, transplantation, or sustained eGFR <15), sustained ≥50% eGFR reduction from baseline, or death | 0.76 | 0.66–0.88 | 331 vs 410 | verified |
| Sustained eGFR decline (≥50 %) Persistent >=50% reduction from baseline in eGFR (component of primary outcome; persistent = two consecutive measurements >=4 weeks apart) | 0.73 | 0.59–0.89 | 165 vs 213 | verified |
| Kidney failure (eGFR <15) Persistent eGFR <15 ml/min/1.73 m2 (component of primary outcome) | 0.80 | 0.61–1.06 | 92 vs 110 | verified |
| Kidney failure (kidney-replacement therapy) Initiation of kidney-replacement therapy (dialysis or transplantation; component of primary outcome) | 0.84 | 0.63–1.12 | 87 vs 100 | verified |
| Major adverse limb events Major adverse limb event, time-to-first-event analysis | 0.56 | 0.30–1.02 | 16 vs 28 | verified |
Verbatim quotes (10)
- 3-point MACE · Results, Confirmatory Secondary Outcomes; Table 2; Figure 1E
The risk of major cardiovascular events was 18% lower in the semaglutide group than in the placebo group (212 vs. 254 events; hazard ratio, 0.82; 95% CI, 0.68 to 0.98; P = 0.029)
- Cardiovascular death · Table 2; Figure 1C
Death from cardiovascular causes 123 (7.0) 169 (9.6) 0.71 (0.56 to 0.89)
- All-cause death · Results, Confirmatory Secondary Outcomes; Table 2; Figure 1F
The risk of death from any cause was 20% lower in the semaglutide group than in the placebo group (227 vs. 279 events; hazard ratio, 0.80; 95% CI, 0.67 to 0.95, P = 0.01)
- Myocardial infarction · Table 2
Nonfatal myocardial infarction 52 (2.9) 64 (3.6) 0.80 (0.55 to 1.15)
- Stroke · Table 2
Nonfatal stroke 63 (3.6) 51 (2.9) 1.22 (0.84 to 1.77)
- Major kidney disease events · Results, Primary Outcome; Table 2; Figure 1A
331 first events [5.8 per 100 patient-years of follow-up] vs. 410 first events [7.5 per 100 patient-years]), ... hazard ratio, 0.76; 95% confidence interval [CI], 0.66 to 0.88; P = 0.0003
- Sustained eGFR decline (≥50 %) · Table 2, components of primary outcome
Persistent ≥50% reduction from baseline in eGFR 165 (9.3) 213 (12.1) 0.73 (0.59 to 0.89)
- Kidney failure (eGFR <15) · Table 2, components of primary outcome
Persistent eGFR <15 ml/min/1.73 m2 92 (5.2) 110 (6.2) 0.80 (0.61 to 1.06)
- Kidney failure (kidney-replacement therapy) · Table 2, components of primary outcome
Initiation of kidney-replacement therapy 87 (4.9) 100 (5.7) 0.84 (0.63 to 1.12)
- Major adverse limb events · Table 2 (continued), lower section
Major adverse limb event in a time-to-first-event analysis — no. of events 16 28 0.56 (0.30 to 1.02)
SOUL oral semaglutide 14 mg vs placebo · T2D + CVD/CKD · n = 9650 · 2025 verified
| Endpoint | HR | 95 % CI | Events, drug vs control | Status |
|---|---|---|---|---|
| 3-point MACE primary Three-point MACE: CV death, nonfatal MI, or nonfatal stroke (time to first event) | 0.86 | 0.77–0.96 | 579 vs 668 | verified |
| Cardiovascular death Death from cardiovascular causes | 0.93 | 0.80–1.09 | 301 vs 320 | verified |
| All-cause death Death from any cause | 0.91 | 0.80–1.02 | 528 vs 577 | verified |
| Myocardial infarction Fatal or nonfatal myocardial infarction | 0.73 | 0.61–0.88 | 200 vs 268 | verified |
| Stroke Fatal or nonfatal stroke | 0.95 | 0.76–1.17 | 164 vs 171 | verified |
| Hospitalisation for heart failure Heart failure (hospitalization for heart failure; supportive secondary outcome, labelled 'Heart failure' in Table 2) | 0.86 | 0.69–1.08 | 146 vs 167 | verified |
| CV death or worsening HF Heart failure events: three-point composite of CV death, urgent visit for heart failure, or hospitalization for heart failure | 0.90 | 0.79–1.03 | 405 vs 443 | verified |
| Kidney composite Major kidney disease events (first confirmatory secondary): five-point composite of CV death, kidney-related death, persistent eGFR decline of >=50%, persistent | 0.91 | 0.80–1.05 | 403 vs 435 | verified |
| Expanded MACE (MACE + revasc. + UA) MACE five-point composite: death from CV causes, nonfatal MI, nonfatal stroke, coronary revascularization, or hospitalization for unstable angina | 0.84 | 0.76–0.93 | 670 vs 777 | verified |
| Major adverse limb events Major adverse limb events, two-point composite: hospitalization for acute limb ischemia or hospitalization for chronic limb ischemia (confirmatory secondary) | 0.71 | 0.52–0.96 | 71 vs 99 | verified |
| Coronary revascularisation Coronary revascularization | 0.75 | 0.62–0.90 | 200 vs 263 | verified |
| Hospitalisation for unstable angina Hospitalization for unstable angina pectoris | 0.92 | 0.67–1.26 | 74 vs 80 | verified |
Verbatim quotes (12)
- 3-point MACE · Results, Primary and Confirmatory Secondary Outcomes; Table
579 of the 4825 participants (12.0%...) in the oral semaglutide group, as compared with 668 of the 4825 participants (13.8%...) in the placebo group (hazard ratio, 0.86; 95% CI, 0.77 to 0.96
- Cardiovascular death · Results, paragraph 2; Table 2; Figure 1B
301 participants (6.2%) in the oral semaglutide group and 320 participants (6.6%) in the placebo group died from cardiovascular causes (hazard ratio, 0.93; 95% CI, 0.80 to 1.09)
- All-cause death · Table 2; Results, Supportive Secondary Outcomes
Death from any cause 528 (10.9) 2.8 577 (12.0) 3.0 0.91 (0.80–1.02)
- Myocardial infarction · Table 2; Results, Supportive Secondary Outcomes
Fatal or nonfatal myocardial infarction 200 (4.1) 1.1 268 (5.6) 1.4 0.73 (0.61–0.88)
- Stroke · Table 2; Results, Supportive Secondary Outcomes
Fatal or nonfatal stroke 164 (3.4) 0.9 171 (3.5) 0.9 0.95 (0.76–1.17)
- Hospitalisation for heart failure · Table 2
Heart failure 146 (3.0) 0.8 167 (3.5) 0.9 0.86 (0.69–1.08)
- CV death or worsening HF · Table 2; Results, Supportive Secondary Outcomes
Heart failure events, three-point composite 405 (8.4) 2.1 443 (9.2) 2.4 0.90 (0.79–1.03)
- Kidney composite · Results, paragraph 4; Table 2; Figure 1E
an event occurred in 403 participants (8.4%...) in the oral semaglutide group, as compared with 435 participants (9.0%...) in the placebo group (hazard ratio, 0.91; 95% CI, 0.80 to 1.05; P = 0.19)
- Expanded MACE (MACE + revasc. + UA) · Table 2, supportive secondary outcomes
Major adverse cardiovascular events, five-point com- posite‖ 670 (13.9) 3.6 777 (16.1) 4.3 0.84 (0.76–0.93)
- Major adverse limb events · Table 2, confirmatory secondary outcomes
Major adverse limb events, two-point composite¶ 71 (1.5) 0.4 99 (2.1) 0.5 0.71 (0.52–0.96)
- Coronary revascularisation · Table 2, supportive secondary outcomes
Coronary revascularization 200 (4.1) 1.1 263 (5.5) 1.4 0.75 (0.62–0.90)
- Hospitalisation for unstable angina · Table 2, supportive secondary outcomes
Hospitalization for unstable angina pectoris 74 (1.5) 0.4 80 (1.7) 0.4 0.92 (0.67–1.26)
SUSTAIN-6 semaglutide 0.5/1.0 mg vs placebo · T2D at high CV risk · n = 3297 · 2016 verified
| Endpoint | HR | 95 % CI | Events, drug vs control | Status |
|---|---|---|---|---|
| 3-point MACE primary First occurrence of CV death, nonfatal MI (including silent), or nonfatal stroke | 0.74 | 0.58–0.95 | 108 vs 146 | verified |
| Cardiovascular death Death from cardiovascular causes | 0.98 | 0.65–1.48 | 44 vs 46 | verified |
| All-cause death Death from any cause | 1.05 | 0.74–1.50 | 62 vs 60 | verified |
| Myocardial infarction Nonfatal myocardial infarction only (fatal MI not reported separately) | 0.74 | 0.51–1.08 | 47 vs 64 | verified |
| Stroke Nonfatal stroke only (fatal stroke not reported separately) | 0.61 | 0.38–0.99 | 27 vs 44 | verified |
| Hospitalisation for heart failure Hospitalization for heart failure | 1.11 | 0.77–1.61 | 59 vs 54 | verified |
| Kidney composite New or worsening nephropathy: persistent macroalbuminuria, persistent doubling of serum creatinine with creatinine clearance <45 ml/min/1.73 m2 (MDRD), or need | 0.64 | 0.46–0.88 | 62 vs 100 | verified |
| Expanded MACE (MACE + HF hosp. + revasc. + UA) Expanded composite: death from CV causes, nonfatal MI, nonfatal stroke, revascularization (coronary or peripheral), and hospitalization for unstable angina or heart failure | 0.74 | 0.62–0.89 | 199 vs 264 | verified |
| Retinopathy complications Diabetic retinopathy complications: vitreous hemorrhage, onset of diabetes-related blindness, or need for treatment with an intravitreal agent or retinal photocoagulation | 1.76 | 1.11–2.78 | 50 vs 29 | verified |
| Coronary revascularisation Revascularization (coronary or peripheral; not coronary-only) | 0.65 | 0.50–0.86 | 83 vs 126 | verified |
| Hospitalisation for unstable angina Hospitalization for unstable angina pectoris | 0.82 | 0.47–1.44 | 22 vs 27 | verified |
Verbatim quotes (11)
- 3-point MACE · Results, Cardiovascular Outcomes, paragraph 1; Table 2
The composite primary outcome occurred in 108 of 1648 patients (6.6%) in the semaglutide group and 146 of 1649 (8.9%) in the placebo group (hazard ratio, 0.74; 95% confidence interval [CI], 0.58 to 0.95
- Cardiovascular death · Results, Cardiovascular Outcomes, paragraph 1; Table 2
deaths reported in 44 patients (2.7%) in the semaglutide group and 46 (2.8%) in the placebo group (hazard ratio, 0.98; 95% CI, 0.65 to 1.48; P = 0.92)
- All-cause death · Table 2
From any cause 62 (3.8) 1.82 60 (3.6) 1.76 1.05 (0.74–1.50) 0.79
- Myocardial infarction · Results, Cardiovascular Outcomes, paragraph 1; Table 2
Nonfatal myocardial infarction occurred in 47 patients (2.9%) in the semaglutide group and 64 (3.9%) in the placebo group (hazard ratio, 0.74; 95% CI, 0.51 to 1.08; P = 0.12)
- Stroke · Results, Cardiovascular Outcomes, paragraph 1; Table 2
Nonfatal stroke occurred in 27 patients (1.6%) in the semaglutide group and 44 (2.7%) in the placebo group (hazard ratio, 0.61; 95% CI, 0.38 to 0.99; P = 0.04)
- Hospitalisation for heart failure · Table 2
Hospitalization for heart failure 59 (3.6) 1.76 54 (3.3) 1.61 1.11 (0.77–1.61) 0.57
- Kidney composite · Results, Microvascular Outcomes; Table 2
New or worsening nephropathy occurred in 62 patients (3.8%) in the semaglutide group and 100 (6.1%) in the placebo group (hazard ratio, 0.64; 95% CI, 0.46 to 0.88; P = 0.005)
- Expanded MACE (MACE + HF hosp. + revasc. + UA) · Table 2
Expanded composite outcome‡ 199 (12.1) 6.17 264 (16.0) 8.36 0.74 (0.62–0.89)
- Retinopathy complications · Table 2
Retinopathy complications§ 50 (3.0) 1.49 29 (1.8) 0.86 1.76 (1.11–2.78)
- Coronary revascularisation · Table 2
Revascularization 83 (5.0) 2.50 126 (7.6) 3.85 0.65 (0.50–0.86)
- Hospitalisation for unstable angina · Table 2
Hospitalization for unstable angina pectoris 22 (1.3) 0.65 27 (1.6) 0.80 0.82 (0.47–1.44)
PIONEER 6 oral semaglutide 14 mg vs placebo · T2D at high CV risk · n = 3183 · 2019 verified
| Endpoint | HR | 95 % CI | Events, drug vs control | Status |
|---|---|---|---|---|
| 3-point MACE primary First occurrence of CV death (including undetermined causes), nonfatal MI, or nonfatal stroke | 0.79 | 0.57–1.11 | 61 vs 76 | verified |
| Cardiovascular death Death from cardiovascular causes (including undetermined causes) | 0.49 | 0.27–0.92 | 15 vs 30 | verified |
| All-cause death Death from any cause | 0.51 | 0.31–0.84 | 23 vs 45 | verified |
| Myocardial infarction Nonfatal myocardial infarction (first events; fatal MI not separately reported) | 1.18 | 0.73–1.90 | 37 vs 31 | verified |
| Stroke Nonfatal stroke (first events; fatal stroke not separately reported) | 0.74 | 0.35–1.57 | 12 vs 16 | verified |
| Hospitalisation for heart failure Heart failure resulting in hospitalization (first events) | 0.86 | 0.48–1.55 | 21 vs 24 | verified |
| Expanded MACE (MACE + HF hosp. + UA) Expanded composite: death from CV causes, nonfatal MI, nonfatal stroke, unstable angina resulting in hospitalization, or heart failure resulting in hospitalization | 0.82 | 0.61–1.10 | 83 vs 100 | verified |
| Hospitalisation for unstable angina Unstable angina resulting in hospitalization | 1.56 | 0.60–4.01 | 11 vs 7 | verified |
Verbatim quotes (8)
- 3-point MACE · Abstract; Results, Cardiovascular Outcomes; Table 2
Major adverse cardiovascular events occurred in 61 of 1591 patients (3.8%) in the oral semaglutide group and 76 of 1592 (4.8%) in the placebo group (hazard ratio, 0.79; 95% confidence interval [CI], 0.57 to 1.11
- Cardiovascular death · Abstract; Table 2
death from cardiovascular causes, 15 of 1591 patients (0.9%) in the oral semaglutide group and 30 of 1592 (1.9%) in the placebo group (hazard ratio, 0.49; 95% CI, 0.27 to 0.92)
- All-cause death · Abstract; Table 2
Death from any cause occurred in 23 of 1591 patients (1.4%) in the oral semaglutide group and 45 of 1592 (2.8%) in the placebo group (hazard ratio, 0.51; 95% CI, 0.31 to 0.84)
- Myocardial infarction · Abstract; Table 2
nonfatal myocardial infarction, 37 of 1591 patients (2.3%) and 31 of 1592 (1.9%), respectively (hazard ratio, 1.18; 95% CI, 0.73 to 1.90)
- Stroke · Abstract; Table 2
nonfatal stroke, 12 of 1591 patients (0.8%) and 16 of 1592 (1.0%), respectively (hazard ratio, 0.74; 95% CI, 0.35 to 1.57)
- Hospitalisation for heart failure · Results, Cardiovascular Outcomes, paragraph 3; Table 2
First events of heart failure resulting in hospitalization occurred in 21 of 1591 patients (1.3%) and 24 of 1592 (1.5%), respectively (hazard ratio, 0.86; 95% CI, 0.48 to 1.55).
- Expanded MACE (MACE + HF hosp. + UA) · Table 2
Expanded composite outcome§ 83 (5.2) 4.0 100 (6.3) 4.9 0.82 (0.61–1.10)
- Hospitalisation for unstable angina · Table 2
Unstable angina resulting in hospitalization 11 (0.7) 0.5 7 (0.4) 0.3 1.56 (0.60–4.01)
Other indications
STEP-HFpEF Semaglutide · HFpEF + obesity · 52 weeks · n = 529 seed
KCCQ-CSS +7.8 points vs placebo; weight −13.3 % vs −2.6 %
| Measure | Drug | Control | Difference (95 % CI) | Status |
|---|---|---|---|---|
| Body weight, percent change from baseline week 52 | −13.3 | −2.6 | −10.7 (−11.9 to −9.4) percentage points | verified |
| KCCQ clinical summary score, change from baseline week 52 | +16.6 | +8.7 | +7.8 (+4.8 to +10.9) points (0-100) | verified |
Verbatim quotes (2)
- Body weight, percent change from baseline
the mean percentage change in body weight was -13.3% with semaglutide and -2.6% with placebo (estimated difference, -10.7 percentage points; 95% CI, -11.9 to -9.4; P<0.001)
- KCCQ clinical summary score, change from baseline
The mean change in the KCCQ-CSS was 16.6 points with semaglutide and 8.7 points with placebo (estimated difference, 7.8 points; 95% confidence interval [CI], 4.8 to 10.9; P<0.001)
STEP-HFpEF DM Semaglutide · HFpEF + obesity + T2D · 52 weeks · n = 616 seed
KCCQ-CSS +7.3 points vs placebo
| Measure | Drug | Control | Difference (95 % CI) | Status |
|---|---|---|---|---|
| Body weight, percent change from baseline week 52 | −9.8 | −3.4 | −6.4 (−7.6 to −5.2) percentage points | verified |
| KCCQ clinical summary score, change from baseline week 52 | +13.7 | +6.4 | +7.3 (+4.1 to +10.4) points (0-100) | verified |
Verbatim quotes (2)
- Body weight, percent change from baseline
the mean percentage change in body weight was -9.8% with semaglutide and -3.4% with placebo (estimated difference, -6.4 percentage points; 95% CI, -7.6 to -5.2; P<0.001)
- KCCQ clinical summary score, change from baseline
The mean change in the KCCQ-CSS was 13.7 points with semaglutide and 6.4 points with placebo (estimated difference, 7.3 points; 95% confidence interval [CI], 4.1 to 10.4; P<0.001)
STEP 9 Semaglutide · Knee osteoarthritis + obesity · 68 weeks · n = 407 seed
WOMAC pain −41.7 vs −27.5 points; weight −13.7 % vs −3.2 %
ESSENCE (part 1) Semaglutide · MASH F2–F3 · 72 weeks · n = 800 seed
Steatohepatitis resolution 62.9 % vs 34.3 %; fibrosis improvement 36.8 % vs 22.4 %; FDA accelerated approval 2025
| Measure | Drug | Control | Difference (95 % CI) | Status |
|---|---|---|---|---|
| Reduction in liver fibrosis (>=1 stage) without worsening of steatohepatitis week 72 | +36.8 | +22.4 | +14.4 (+7.5 to +21.3) percentage points | verified |
| Resolution of steatohepatitis without worsening of fibrosis week 72 | +62.9 | +34.3 | +28.7 (+21.1 to +36.2) percentage points | verified |
Verbatim quotes (2)
- Reduction in liver fibrosis (>=1 stage) without worsening of steatohepatitis
A reduction in liver fibrosis without worsening of steatohepatitis was reported in 36.8% of the patients in the semaglutide group and in 22.4% of those in the placebo group (estimated difference, 14.4 percentage points; 95% CI, 7.5 to 21.3; P<0.001)
- Resolution of steatohepatitis without worsening of fibrosis
Resolution of steatohepatitis without worsening of fibrosis occurred in 62.9% of the 534 patients in the semaglutide group and in 34.3% of the 266 patients in the placebo group (estimated difference, 28.7 percentage points; 95% confidence interval [CI], 21.1 to 36.2; P<0.001)
FLOW Semaglutide · CKD + T2D · 178 weeks · n = 3533 seed
Major kidney events HR 0.76; all-cause death HR 0.80
| Measure | Drug | Control | Difference (95 % CI) | Status |
|---|---|---|---|---|
| Major kidney disease events (kidney failure, >=50% eGFR reduction, kidney or CV death) week 177 | +331.0 | +410.0 | +0.8 (+0.7 to +0.9) hazard ratio | verified |
Verbatim quotes (1)
- Major kidney disease events (kidney failure, >=50% eGFR reduction, kidney or CV death)
The risk of a primary-outcome event was 24% lower in the semaglutide group than in the placebo group (331 vs. 410 first events; hazard ratio, 0.76; 95% confidence interval [CI], 0.66 to 0.88; P = 0.0003)
evoke / evoke+ Semaglutide · Early Alzheimer's disease · 104 weeks · n = 3680 seed
Primary endpoint (CDR-SB) not met (announced Nov 2025)
| Measure | Drug | Control | Difference (95 % CI) | Status |
|---|---|---|---|---|
| CDR-SB, change from baseline evoke week 104 | +2.3 | +2.3 | −0.1 (−0.3 to +0.2) points (0-18) | verified |
| CDR-SB, change from baseline evoke+ week 104 | +2.2 | +2.1 | +0.1 (−0.2 to +0.4) points (0-18) | verified |
Verbatim quotes (2)
- CDR-SB, change from baseline
mean changes in CDR-SB score from baseline to week 104 were 2·3 (SE 0·1) and 2·2 (0·1) with semaglutide, compared with 2·3 (0·1) and 2·1 (0·1) with placebo (estimated difference -0·08 [95% CI -0·35 to 0·20], p=0·57 in evoke and 0·10 [-0·17 to 0·38], p=0·46 in evoke+)
- CDR-SB, change from baseline
mean changes in CDR-SB score from baseline to week 104 were 2·3 (SE 0·1) and 2·2 (0·1) with semaglutide, compared with 2·3 (0·1) and 2·1 (0·1) with placebo (estimated difference -0·08 [95% CI -0·35 to 0·20], p=0·57 in evoke and 0·10 [-0·17 to 0·38], p=0·46 in evoke+)
Registered trials (155)
From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.
| Trial | Indication | Phase | Status | Start → primary completion | n | Result | Registry |
|---|---|---|---|---|---|---|---|
| NCT07797036 Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes Mellitus | Other | Phase 3 | not yet recruiting | 2027-09 → 2030-09 | 226 | not yet recruiting | NCT07797036 |
| S-CUD Semaglutide for the Treatment of Cannabis Use Disorder | Addiction | Phase 2 | not yet recruiting | 2027-01 → 2029-01 | 40 | not yet recruiting | NCT07879612 |
| VITAL-H Validation & Intervention Testing for Aging, Longevity and Healthspan | Other | Phase 2 | not yet recruiting | 2027-01 → 2030-12 | 1200 | not yet recruiting | NCT07923630 |
| SPOT-DM Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus | Other | Phase 3 | not yet recruiting | 2026-12 → 2029-06 | 37 | not yet recruiting | NCT06913023 |
| NCT07642635 Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy | Other | Phase 2 | recruiting | 2026-12 → 2030-09 | 30 | recruiting | NCT07642635 |
| ESCaMS Trial Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome | Other | Phase 3 | not yet recruiting | 2026-12 → 2030-07 | 600 | not yet recruiting | NCT07770282 |
| SEMAFORCRANIO SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years | Obesity | Phase 3 | not yet recruiting | 2026-11 → 2031-02 | 50 | not yet recruiting | NCT07845994 |
| LEAST Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy | Neurology | Phase 2 | not yet recruiting | 2026-10 → 2028-10 | 100 | not yet recruiting | NCT07511543 |
| WE-FiERCE Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometrium | Other | Phase 2 | recruiting | 2026-09 → 2029-02 | 71 | recruiting | NCT06073184 |
| NCT06934655 Early Reinitiation of Semaglutide Post-Sleeve Gastrectomy in Youth | Obesity | Phase 3 | recruiting | 2026-09 → 2030-11 | 150 | recruiting | NCT06934655 |
| SHIFT Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study | Addiction | Phase 2 | not yet recruiting | 2026-09 → 2027-01 | 40 | not yet recruiting | NCT07509112 |
| NCT07651319 Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease | Alzheimer's | Phase 2 | recruiting | 2026-09 → 2029-06 | 30 | recruiting | NCT07651319 |
| UNIGUIDE-2 Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2) | T2D | Phase 3 | recruiting | 2026-09 → 2028-02 | 956 | recruiting | NCT07653477 |
| OASIS 5 Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight | Obesity | Phase 3 | recruiting | 2026-08 → 2028-02 | 450 | recruiting | NCT07770841 |
| CRAVE Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE) | Addiction | Phase 3 | recruiting | 2026-07 → 2029-03 | 622 | recruiting | NCT07218354 |
| PLASTIC Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity | Obesity | Phase 3 | not yet recruiting | 2026-06 → 2031-04 | 120 | not yet recruiting | NCT07021937 |
| NCT07282769 Semaglutide (Wegovy) Treatment for Trichotillomania | Other | Phase 2 | not yet recruiting | 2026-06 → 2027-02 | 10 | not yet recruiting | NCT07282769 |
| GLICH GLP-1 Receptor Agonist in Primary Intracerebral Hemorrhage: A Phase 2 Randomized Trial | Neurology | Phase 2 | not yet recruiting | 2026-06 → 2028-06 | 200 | not yet recruiting | NCT07613437 |
| GLOW Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes | T2D | Phase 3 | recruiting | 2026-05 → 2028-11 | 20 | recruiting | NCT07428746 |
| GL1DER HIV RCT GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV | Addiction | Phase 2 | recruiting | 2026-04 → 2029-10 | 200 | recruiting | NCT07221214 |
| NCT07466017 A Study of CS060380 Tablets in Patients With MASH and Obesity | MASH | Phase 2 | active not recruiting | 2026-04 → 2027-04 | 130 | active not recruiting | NCT07466017 |
| HASHTAG Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder | Addiction | Phase 2 | recruiting | 2026-04 → 2028-04 | 100 | recruiting | NCT07523633 |
| SEMAFOOT2 Effect of Semaglutide on Healing of Foot Ulcers in Type 2 Diabetes Patients | T2D | Phase 3 | recruiting | 2026-04 → 2028-12 | 52 | recruiting | NCT07581145 |
| NCT06975111 Focusing on the Menopausal Transition to Improve Mid-Life Women's Health | Other | Phase 3 | recruiting | 2026-03 → 2029-10 | 200 | recruiting | NCT06975111 |
| GLP1-SC Semaglutide for Smoking Cessation in Patients With Diabetes | Addiction | Phase 3 | recruiting | 2026-02 → 2026-12 | 100 | recruiting | NCT07059377 |
| GEM Glutide for Ending Methamphetamine | Addiction | Phase 2 | recruiting | 2026-02 → 2030-02 | 162 | recruiting | NCT07204249 |
| REST Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: Recovery Effects After Semaglutide Termination | Obesity | Phase 3 | recruiting | 2026-02 → 2028-09 | 98 | recruiting | NCT07294950 |
| REINFORCE Incretin Microdosing for Cardiometabolic Health in People With HIV | Other | Phase 2 | recruiting | 2026-02 → 2028-05 | 30 | recruiting | NCT07325500 |
| HARP Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide | Addiction | Phase 2 | recruiting | 2026-01 → 2027-06 | 30 | recruiting | NCT07040592 |
| NCT07135245 Improved Treatment and Monitoring of Alzheimer's Disease | Alzheimer's | Phase 2 | not yet recruiting | 2026-01 → 2030-09 | 180 | not yet recruiting | NCT07135245 |
| NCT07227948 Repurposing Semaglutide for the Treatment of Cocaine Use Disorder | Addiction | Phase 2 | recruiting | 2026-01 → 2029-01 | 75 | recruiting | NCT07227948 |
| NCT07271251 · Japan A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 Diabetes | T2D | Phase 3 | completed | 2025-12 → 2026-06 | 267 | Completed; results not in the atlas yet | NCT07271251 |
| GALACTUS Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial) | Other | Phase 3 | completed | 2025-12 → 2026-10 | 44 | Completed; results not in the atlas yet | NCT07295223 |
| EPIC-CT Epicardial Cardiac Fat-CT (EPIC-CT) | Other | Phase 3 | recruiting | 2025-12 → 2027-01 | 136 | recruiting | NCT07297589 |
| NCT07820111 Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial | Obesity | Phase 3 | completed | 2025-10 → 2026-03 | 159 | Completed; results not in the atlas yet | NCT07820111 |
| NCT07200622 Oral Semaglutide in Patients With Alzheimer's Disease | Alzheimer's | Phase 2 | not yet recruiting | 2025-09 → 2027-12 | 60 | not yet recruiting | NCT07200622 |
| STAC Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV | Addiction | Phase 2 | active not recruiting | 2025-08 → 2027-01 | 40 | active not recruiting | NCT06691243 |
| STARS Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial | Neurology | Phase 3 | not yet recruiting | 2025-07 → 2027-07 | 436 | not yet recruiting | NCT07030621 |
| SHORE Semaglutide for Helping Opioid Recovery | Addiction | Phase 2 | recruiting | 2025-06 → 2027-09 | 46 | recruiting | NCT06639464 |
| SYNCARDIA-HF Effects of Dapagliflozin, Semaglutide, and Their Combination in Heart Failure Patients With Prosthetic Heart Valves | HFpEF | Phase 2 | completed | 2025-06 → 2026-04 | 160 | Completed; results not in the atlas yet | NCT07610174 |
| SEMINAL-AF Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation | Obesity | Phase 3 | recruiting | 2025-04 → 2027-12 | 200 | recruiting | NCT06499857 |
| PCOS Semaglutide vs Metformin in Polycystic Ovary Syndrome (PCOS) | Obesity | Phase 3 | unknown | 2025-03 → 2025-09 | 60 | unknown | NCT05646199 |
| NCT06738979 A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects | Obesity | Phase 3 | completed | 2025-03 → 2026-03 | 408 | Completed; results not in the atlas yet | NCT06738979 |
| SEMPSO Effect of Semaglutide in Patients With Psoriasis and Obesity | Obesity | Phase 3 | recruiting | 2025-03 → 2026-07 | 14 | recruiting | NCT06937060 |
| GALLOP2 Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment | Neurology | Phase 3 | not yet recruiting | 2025-02 → 2028-02 | 390 | not yet recruiting | NCT06788626 |
| FINESSE-CKD Optimizing Albuminuria Treatment in CKD With Finerenone and Semaglutide | CKD | Phase 2 | completed | 2025-02 → 2026-08 | 41 | Completed; results not in the atlas yet | NCT07819227 |
| NCT06548490 GLP-1R Agonist Treatment for Opioid Use Disorder | Addiction | Phase 2 | recruiting | 2025-01 → 2027-04 | 200 | recruiting | NCT06548490 |
| NCT06896981 Semaglutide in Women With Polycystic Ovary Syndrome and Obesity | Obesity | Phase 3 | completed | 2025-01 → 2025-10 | 31 | Completed; results not in the atlas yet | NCT06896981 |
| NCT06717698 A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease | CKD | Phase 2 | recruiting | 2024-12 → 2026-09 | 465 | recruiting | NCT06717698 |
| NCT06616961 Efficacy and Safety of Semaglutide for Weight Loss in Overweight or Obese Adults in Bangladesh With or Without Type 2 Diabetes Mellitus | Obesity | Phase 3 | unknown | 2024-11 → 2025-02 | 480 | unknown | NCT06616961 |
| NCT06633783 A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy® | Obesity | Phase 3 | unknown | 2024-10 → 2026-05 | 370 | unknown | NCT06633783 |
| CAPTIVATE The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect | CKD | Phase 3 | recruiting | 2024-09 → 2029-12 | 2000 | recruiting | NCT06058585 |
| NCT06604624 Semaglutide in Treatment of Obesity | Obesity | Phase 3 | completed | 2024-09 → 2025-08 | 462 | Completed; results not in the atlas yet | NCT06604624 |
| PROTECT Semaglutide in Auto-HSCT | Other | Phase 2 | not yet recruiting | 2024-08 → 2026-12 | 40 | not yet recruiting | NCT06449625 |
| SEMAHEART Mechanisms of Semaglutide Therapy in Heart Failure Patients | HFpEF | Phase 2 | unknown | 2024-07 → 2025-07 | 10 | unknown | NCT06541509 |
| NCT06361823 Exploratory Study on the Efficacy and Safety of Semaglutide for Idiopathic Intracranial Hypertension Treatment | Neurology | Phase 3 | unknown | 2024-05 → 2024-12 | 74 | unknown | NCT06361823 |
| NCT06173778 Semaglutide for Post-Smoking Cessation Weight Management | Addiction | Phase 2 | recruiting | 2024-04 → 2028-05 | 197 | recruiting | NCT06173778 |
| NCT06339086 Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 Diabetes | T2D | Phase 3 | unknown | 2024-04 → 2025-08 | 478 | unknown | NCT06339086 |
| FIT-HF Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure | HFpEF | Phase 3 | recruiting | 2024-04 → 2027-12 | 100 | recruiting | NCT06423599 |
| NCT05424003 Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant | Other | Phase 2 | recruiting | 2024-02 → 2026-08 | 50 | recruiting | NCT05424003 |
| NCT06161844 Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus | T2D | Phase 3 | completed | 2024-02 → 2025-05 | 506 | Completed; results not in the atlas yet | NCT06161844 |
| AUD Clinical Trial of Rybelsus (Semaglutide) Among Adults With Alcohol Use Disorder (AUD) | Addiction | Phase 2 | completed | 2024-01 → 2025-11 | 50 | Completed; results not in the atlas yet | NCT05892432 |
| NCT06072963 COMMETS- Combination MCI Metabolic Syndrome | Other | Phase 2 | recruiting | 2024-01 → 2027-12 | 80 | recruiting | NCT06072963 |
| RESTORE Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome | Obesity | Phase 3 | recruiting | 2023-11 → 2028-02 | 80 | recruiting | NCT05819853 |
| NCT05788965 Semaglutide in CFRD | Obesity | Phase 3 | completed | 2023-10 → 2024-12 | 8 | Completed; results not in the atlas yet | NCT05788965 |
| HALLMARK The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients | CKD | Phase 2 | recruiting | 2023-10 → 2027-10 | 20 | recruiting | NCT05938712 |
| STAR Semaglutide Therapy for Alcohol Reduction (STAR) | Addiction | Phase 2 | active not recruiting | 2023-10 → 2027-03 | 63 | active not recruiting | NCT06015893 |
| SERENA Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes | Other | Phase 3 | recruiting | 2023-09 → 2030-03 | 252 | recruiting | NCT05569772 |
| NCT05813912 A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes | T2D | Phase 3 | completed | 2023-09 → 2025-04 | 148 | Completed; results not in the atlas yet | NCT05813912 |
| STEP12 A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range | Obesity | Phase 3 | completed | 2023-09 → 2025-04 | 242 | Completed; results not in the atlas yet | NCT06041217 |
| WP3 Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study | CKD | Phase 2 | terminated | 2023-08 → 2024-09 | 1 | Terminated | NCT05897372 |
| GALLOP Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies | Neurology | Phase 2 | completed | 2023-08 → 2024-10 | 140 | Completed; results not in the atlas yet | NCT05920889 |
| NCT05067621 Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease | MASH | Phase 2 | active not recruiting | 2023-07 → 2026-12 | 60 | active not recruiting | NCT05067621 |
| STEP Young A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight | Obesity | Phase 3 | active not recruiting | 2023-07 → 2025-10 | 212 | active not recruiting | NCT05726227 |
| STAR-T Semaglutide Therapy for Alcohol Reduction - Tulsa | Addiction | Phase 2 | completed | 2023-07 → 2025-07 | 80 | Completed; results not in the atlas yet | NCT05891587 |
| NCT05950516 Efficacy and Safety of Semaglutide Ingection in Subjects With Type 2 Diabetes | T2D | Phase 3 | unknown | 2023-07 → 2024-11 | 478 | unknown | NCT05950516 |
| NCT05891496 A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease | Alzheimer's | Phase 3 | completed | 2023-06 → 2024-08 | 23 | Completed; results not in the atlas yet | NCT05891496 |
| SEMALCO Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity? | Addiction | Phase 2 | completed | 2023-06 → 2025-07 | 108 | Completed; results not in the atlas yet | NCT05895643 |
| OASIS 3 Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3) | Obesity | Phase 3 | completed | 2023-05 → 2025-01 | 200 | Completed; results not in the atlas yet | NCT05890976 |
| ASSET Acute Subcutaneous SemaglutidE in Acute Ischemic sTroke | Neurology | Phase 2 | recruiting | 2023-04 → 2025-09 | 380 | recruiting | NCT05630586 |
| SURMOUNT-5 A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities | Obesity | Phase 3 | completed | 2023-04 → 2024-11 | 751 | Completed; arm-level results are in the atlas maps (Effect vs cost, Arms) | NCT05822830 |
| KLIN-HEALTH Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter Syndrome | Other | Phase 3 | recruiting | 2023-03 → 2027-04 | 150 | recruiting | NCT05586802 |
| STEP UP A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP) | Obesity | Phase 3 | completed | 2023-01 → 2024-10 | 1407 | Completed; arm-level results are in the atlas maps (Effect vs cost, Arms) | NCT05646706 |
| NCT05649137 A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight | Obesity | Phase 3 | completed | 2023-01 → 2024-10 | 512 | Completed; results not in the atlas yet | NCT05649137 |
| LSS Latino Semaglutide Study | Obesity | Phase 3 | completed | 2022-12 → 2024-05 | 119 | Completed; results not in the atlas yet | NCT05087342 |
| BARI-STEP Semaglutide 2.4 mg in Patients With Poor Weight-loss | Obesity | Phase 3 | completed | 2022-11 → 2025-04 | 70 | Completed; results not in the atlas yet | NCT05073835 |
| NCT05530577 Effects of Semaglutide on Nicotine Intake | Addiction | Phase 2 | completed | 2022-10 → 2024-05 | 24 | Completed; results not in the atlas yet | NCT05530577 |
| OASIS 4 Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range | Obesity | Phase 3 | completed | 2022-10 → 2024-04 | 307 | Completed; arm-level results are in the atlas maps (Effect vs cost, Arms) | NCT05564117 |
| NCT05520775 Semaglutide for Alcohol Use Disorder | Addiction | Phase 2 | completed | 2022-09 → 2024-04 | 48 | Completed; results not in the atlas yet | NCT05520775 |
| NCT04998136 · Korea Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity | Obesity | Phase 3 | completed | 2022-08 → 2023-10 | 150 | Completed; results not in the atlas yet | NCT04998136 |
| NCT05478252 A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes | T2D | Phase 3 | completed | 2022-08 → 2023-08 | 388 | Completed; results not in the atlas yet | NCT05478252 |
| SUSTAIN OPTIMIZE A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE) | T2D | Phase 3 | completed | 2022-08 → 2025-03 | 573 | Completed; results not in the atlas yet | NCT05514535 |
| TOLEDDO Effect of Weekly GLP1 Agonist Treatment in "Double Diabetes" | Other | Phase 3 | recruiting | 2022-07 → 2028-08 | 76 | recruiting | NCT05305794 |
| NCT05816057 A Study of the Efficacy and Safety of Semaglutide Injection in the Treatment of Type 2 Diabetes Mellitus | T2D | Phase 3 | completed | 2022-07 → 2023-07 | 476 | Completed; results not in the atlas yet | NCT05816057 |
| COMBINE 2 A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2) | T2D | Phase 3 | completed | 2022-04 → 2023-12 | 683 | Completed; results not in the atlas yet | NCT05259033 |
| SMART SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes | CKD | Phase 3 | completed | 2022-03 → 2024-05 | 125 | Completed; results not in the atlas yet | NCT04889183 |
| HISTORI Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes | Other | Phase 2 | completed | 2022-01 → 2024-03 | 154 | Completed; results not in the atlas yet | NCT05193578 |
| SEPLA Effect Of Semaglutide In Coronary Atheroma Plaque | Other | Phase 3 | unknown | 2021-11 → 2024-12 | 120 | unknown | NCT05071417 |
| OASIS 2 Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity | Obesity | Phase 3 | completed | 2021-11 → 2023-07 | 201 | Completed; results not in the atlas yet | NCT05132088 |
| STEP 9 Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis | Knee OA | Phase 3 | completed | 2021-10 → 2023-07 | 407 | WOMAC pain −41.7 vs −27.5 points | NCT05064735 |
| NCT04466345 Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder | Alzheimer's | Phase 2 | completed | 2021-10 → 2024-12 | 72 | Completed; results not in the atlas yet | NCT04466345 |
| SEMPATICO Semaglutide to Reduce Myocardial Injury in PATIents With COVID-19 | Other | Phase 2 | unknown | 2021-09 → 2022-03 | 400 | unknown | NCT04615871 |
| OASIS 1 Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1) | Obesity | Phase 3 | completed | 2021-09 → 2023-03 | 667 | Completed; results not in the atlas yet | NCT05035095 |
| STEP 10 Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes | Obesity | Phase 3 | completed | 2021-09 → 2023-01 | 207 | Completed; results not in the atlas yet | NCT05040971 |
| WAYFIND Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) | MASH | Phase 2 | completed | 2021-08 → 2024-11 | 457 | Completed; results not in the atlas yet | NCT04971785 |
| NCT05016882 Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH) | MASH | Phase 2 | completed | 2021-08 → 2024-12 | 698 | Completed; results not in the atlas yet | NCT05016882 |
| RAISE-KT Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy | CKD | Phase 3 | terminated | 2021-07 → 2023-01 | 15 | Terminated | NCT04741074 |
| STEP-HFpEF DM Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes | HFpEF | Phase 3 | completed | 2021-06 → 2023-10 | 617 | KCCQ-CSS +7.3 points vs placebo | NCT04916470 |
| evoke / evoke+ A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) | Alzheimer's | Phase 3 | completed | 2021-05 → 2025-09 | 1840 | CDR-SB primary endpoint not met | NCT04777396 |
| EVOKE Plus A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) | Alzheimer's | Phase 3 | completed | 2021-05 → 2025-09 | 1840 | CDR-SB primary endpoint not met (with evoke) | NCT04777409 |
| ESSENCE (part 1) Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH) | MASH | Phase 3 | active not recruiting | 2021-04 → 2029-04 | 1205 | MASH resolution 62.9 % vs 34.3 % | NCT04822181 |
| REMODEL A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial) | CKD | Phase 3 | completed | 2021-04 → 2024-11 | 106 | Completed; results not in the atlas yet | NCT04865770 |
| STEP-HFpEF Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity | HFpEF | Phase 3 | completed | 2021-03 → 2023-04 | 529 | KCCQ-CSS +7.8 points vs placebo | NCT04788511 |
| The SLIM LIVER Study Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study) | MASH | Phase 2 | completed | 2021-02 → 2023-03 | 51 | Completed; results not in the atlas yet | NCT04216589 |
| PIONEER PLUS Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes | T2D | Phase 3 | completed | 2021-01 → 2023-03 | 1606 | Completed; results not in the atlas yet | NCT04707469 |
| STEP7 Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity. | Obesity | Phase 3 | completed | 2020-12 → 2022-08 | 375 | Completed; results not in the atlas yet | NCT04251156 |
| PIONEER TEENS A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes | T2D | Phase 3 | completed | 2020-11 → 2025-04 | 132 | Completed; results not in the atlas yet | NCT04596631 |
| STRIDE A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes | CV outcomes | Phase 3 | completed | 2020-10 → 2024-06 | 792 | Completed; results not in the atlas yet | NCT04560998 |
| SEMAT The Effects of Semaglutide vs Testosterone Replacement Therapy on Functional Hypogonadism and Sperm Quality in Men With Type 2 Diabetes Mellitus and Obesity | Obesity | Phase 3 | completed | 2020-09 → 2023-05 | 25 | Completed; results not in the atlas yet | NCT06489457 |
| NCT04447859 16-week Flexible vs. 8-week Semaglutide Titration | T2D | Phase 3 | unknown | 2020-02 → 2022-05 | 100 | unknown | NCT04447859 |
| NCT04102189 A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity | Obesity | Phase 3 | completed | 2019-10 → 2022-03 | 201 | Completed; results not in the atlas yet | NCT04102189 |
| PIONEER 11 A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes | T2D | Phase 3 | completed | 2019-10 → 2021-09 | 521 | Completed; results not in the atlas yet | NCT04109547 |
| NAFLD HEROES Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES) | MASH | Phase 2 | recruiting | 2019-07 → 2028-08 | 104 | recruiting | NCT03884075 |
| NCT03987074 Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH) | MASH | Phase 2 | completed | 2019-07 → 2020-07 | 109 | Completed; results not in the atlas yet | NCT03987074 |
| SURPASS-2 A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes | T2D | Phase 3 | completed | 2019-07 → 2021-01 | 1879 | Completed; results not in the atlas yet | NCT03987919 |
| PIONEER 12 A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes | T2D | Phase 3 | completed | 2019-07 → 2021-10 | 1441 | Completed; results not in the atlas yet | NCT04017832 |
| FLOW A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease | CKD | Phase 3 | completed | 2019-06 → 2024-01 | 3533 | Kidney composite HR 0.76 (0.66–0.88) | NCT03819153 |
| SOUL A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes | CV outcomes | Phase 3 | completed | 2019-06 → 2024-08 | 9651 | MACE HR 0.86 (0.77–0.96) | NCT03914326 |
| NCT03987451 A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage | MASH | Phase 2 | completed | 2019-06 → 2021-04 | 71 | Completed; results not in the atlas yet | NCT03987451 |
| SUSTAIN FORTE A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes | T2D | Phase 3 | completed | 2019-06 → 2020-09 | 961 | Completed; results not in the atlas yet | NCT03989232 |
| FOCUS A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes | T2D | Phase 3 | active not recruiting | 2019-05 → 2027-11 | 1500 | active not recruiting | NCT03811561 |
| TEAL Treating PCOS With Semaglutide vs Active Lifestyle Intervention | Obesity | Phase 3 | completed | 2019-05 → 2023-10 | 60 | Completed; results not in the atlas yet | NCT03919929 |
| GIPD GLP1R in Parkinson's Disease | Neurology | Phase 2 | unknown | 2019-01 → 2024-12 | 120 | unknown | NCT03659682 |
| STEP 6 STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity | Obesity | Phase 3 | completed | 2019-01 → 2020-11 | 401 | Completed; results not in the atlas yet | NCT03811574 |
| SELECT Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity | CV outcomes | Phase 3 | completed | 2018-10 → 2023-06 | 17604 | MACE HR 0.80 (0.72–0.90) | NCT03574597 |
| SUSTAIN 11 A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes | T2D | Phase 3 | completed | 2018-10 → 2021-02 | 2274 | Completed; results not in the atlas yet | NCT03689374 |
| STEP 5 Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity | Obesity | Phase 3 | completed | 2018-10 → 2021-01 | 304 | Completed; results not in the atlas yet | NCT03693430 |
| STEP 3 Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program | Obesity | Phase 3 | completed | 2018-08 → 2020-03 | 611 | Completed; results not in the atlas yet | NCT03611582 |
| STEP 1 STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity | Obesity | Phase 3 | completed | 2018-06 → 2020-03 | 1961 | Completed; arm-level results are in the atlas maps (Effect vs cost, Arms) | NCT03548935 |
| STEP 4 Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity | Obesity | Phase 3 | completed | 2018-06 → 2020-02 | 902 | Completed; results not in the atlas yet | NCT03548987 |
| STEP 2 Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity | Obesity | Phase 3 | completed | 2018-06 → 2020-03 | 1210 | Completed; arm-level results are in the atlas maps (Effect vs cost, Arms) | NCT03552757 |
| SUSTAIN - CHINA MRCT Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT) | T2D | Phase 3 | completed | 2017-08 → 2019-03 | 868 | Completed; results not in the atlas yet | NCT03061214 |
| SUSTAIN 9 Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus | T2D | Phase 3 | completed | 2017-03 → 2018-07 | 302 | Completed; results not in the atlas yet | NCT03086330 |
| SUSTAIN 8 Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes | T2D | Phase 3 | completed | 2017-03 → 2018-10 | 788 | Completed; results not in the atlas yet | NCT03136484 |
| PIONEER 8 Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin | T2D | Phase 3 | completed | 2017-02 → 2018-01 | 731 | Completed; results not in the atlas yet | NCT03021187 |
| PIONEER 6 A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes | CV outcomes | Phase 3 | completed | 2017-01 → 2018-09 | 3183 | MACE HR 0.79 (0.57–1.11): non-inferior | NCT02692716 |
| PIONEER 10 Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes | T2D | Phase 3 | completed | 2017-01 → 2018-07 | 458 | Completed; results not in the atlas yet | NCT03015220 |
| NCT02970942 Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis. | MASH | Phase 2 | completed | 2016-11 → 2020-02 | 320 | Completed; results not in the atlas yet | NCT02970942 |
| PIONEER 5 Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment | T2D | Phase 3 | completed | 2016-09 → 2018-04 | 324 | Completed; results not in the atlas yet | NCT02827708 |
| PIONEER 7 Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus. | T2D | Phase 3 | completed | 2016-09 → 2018-02 | 504 | Completed; results not in the atlas yet | NCT02849080 |
| PIONEER 1 Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only | T2D | Phase 3 | completed | 2016-09 → 2017-10 | 703 | Completed; results not in the atlas yet | NCT02906930 |
| PIONEER 2 Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus | T2D | Phase 3 | completed | 2016-08 → 2017-08 | 822 | Completed; results not in the atlas yet | NCT02863328 |
| PIONEER 3 Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes | T2D | Phase 3 | completed | 2016-02 → 2017-02 | 1864 | Completed; results not in the atlas yet | NCT02607865 |
| SUSTAIN 7 Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes. | T2D | Phase 3 | completed | 2016-01 → 2017-04 | 1201 | Completed; results not in the atlas yet | NCT02648204 |
| SUSTAIN-6 Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes | CV outcomes | Phase 3 | completed | 2013-02 → 2016-03 | 3297 | MACE HR 0.74 (0.58–0.95) | NCT01720446 |
Primary sources
- Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. PMID: 33567185.
- Novo Nordisk A/S. Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity (STEP 1). ClinicalTrials.gov identifier NCT03548935. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT03548935
- Novo Nordisk A/S. Effect and Safety of Semaglutide 7.2 mg Once-weekly in Participants With Obesity (STEP UP). ClinicalTrials.gov identifier NCT05646706. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT05646706
- Wharton S, Freitas P, Hjelmesæth J, Kabisch M, Kandler K, Lingvay I, et al. Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025;13(11):949-963. PMID: 40961952.
- Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971-984. PMID: 33667417.
- Novo Nordisk A/S. Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity and Type 2 Diabetes (STEP 2). ClinicalTrials.gov identifier NCT03552757. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT03552757
- Novo Nordisk A/S. Efficacy and Safety of Oral Semaglutide 25 mg Once Daily in Adults With Overweight or Obesity (OASIS 4). ClinicalTrials.gov identifier NCT05564117. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT05564117
- Wharton S, Lingvay I, Bogdanski P, Duque do Vale R, Jacob S, Karlsson T, et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. N Engl J Med. 2025;393(11):1077-1087. PMID: 40934115.
- Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. PMID: 37952131.
- Novo Nordisk A/S. SELECT - Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT). ClinicalTrials.gov identifier NCT03574597. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT03574597
- Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391(2):109-121. PMID: 38785209.
- Novo Nordisk A/S. Effect of Semaglutide Versus Placebo on the Progression of Renal Impairment in Subjects With Type 2 Diabetes and Chronic Kidney Disease (FLOW). ClinicalTrials.gov identifier NCT03819153. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT03819153
- McGuire DK, Marx N, Mulvagh SL, Deanfield JE, Inzucchi SE, Pop-Busui R, et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. N Engl J Med. 2025;392(20):2001-2012. PMID: 40162642.
- Novo Nordisk A/S. Semaglutide Cardiovascular Outcomes Trial in Patients With Type 2 Diabetes (SOUL). ClinicalTrials.gov identifier NCT03914326. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT03914326
- Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844. PMID: 27633186.
- Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2019;381(9):841-851. PMID: 31185157.
- Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023;389(12):1069-1084. PMID: 37622681.
- Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Davies MJ, Hovingh GK, et al. Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes. N Engl J Med. 2024;390(15):1394-1407. PMID: 38587233.
- Bliddal H, Bays H, Czernichow S, Uddén Hemmingsson J, Hjelmesæth J, Hoffmann Morville T, et al. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. N Engl J Med. 2024;391(17):1573-1583. PMID: 39476339.
- Sanyal AJ, Newsome PN, Kliers I, Østergaard LH, Long MT, Kjær MS, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025;392(21):2089-2099. PMID: 40305708.
- Novo Nordisk A/S. A Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer´s Disease (EVOKE) (EVOKE). ClinicalTrials.gov identifier NCT04777396. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT04777396
- Novo Nordisk A/S. A Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer´s Disease (EVOKE Plus) (EVOKE Plus). ClinicalTrials.gov identifier NCT04777409. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT04777409
- Cummings JL, Atri A, Sano M, Zetterberg H, Scheltens P, Knop FK, et al. Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials. Lancet. 2026;407(10544):2167-2179. PMID: 41865758.
How to cite this page
Cite the primary publication for any single result; every value above links to it.